Antibody data
- Antibody Data
- Antigen structure
- References [9]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 66220-1-Ig - Provider product page
- Provider
- Proteintech Group
- Product name
- PD-1/CD279 antibody
- Antibody type
- Monoclonal
- Description
- PD-1/CD279 antibody (Cat. #66220-1-Ig) is a mouse monoclonal antibody that shows reactivity with human, rat, mouse and has been validated for the following applications: FC, IF, IHC, WB,ELISA.
- Reactivity
- Human, Mouse, Rat
- Host
- Mouse
- Conjugate
- Unconjugated
- Isotype
- IgG
- Antibody clone number
- 4H4D1
- Vial size
- 20ul, 150ul
Submitted references The immunomodulatory effect of microglia on ECM neuroinflammation via the PD-1/PD-L1 pathway.
Overcoming PD-1 Inhibitor Resistance with a Monoclonal Antibody to Secreted Frizzled-Related Protein 2 in Metastatic Osteosarcoma.
The mRNA expression of Il6 and Pdcd1 are predictive and protective factors for doxorubicin‑induced cardiotoxicity.
Targeted elimination of myeloid-derived suppressor cells via regulation of the STAT pathway alleviates tumor immunosuppression in neuroblastoma.
Elevated lymphocyte specific protein 1 expression is involved in the regulation of leukocyte migration and immunosuppressive microenvironment in glioblastoma.
Berberine Maintains the Neutrophil N1 Phenotype to Reverse Cancer Cell Resistance to Doxorubicin.
Survival analysis with regard to PD-L1 and CD155 expression in human small cell lung cancer and a comparison with associated receptors.
m6A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade.
Programmed cell death ligand 1 (PD-L1) expression is not a predominant feature in Ewing sarcomas.
Shen Y, Li Y, Zhu Q, Wang J, Huang Y, Liang J, Wu X, Zhao Y
CNS neuroscience & therapeutics 2022 Jan;28(1):46-63
CNS neuroscience & therapeutics 2022 Jan;28(1):46-63
Overcoming PD-1 Inhibitor Resistance with a Monoclonal Antibody to Secreted Frizzled-Related Protein 2 in Metastatic Osteosarcoma.
Nasarre P, Garcia DI, Siegel JB, Bonilla IV, Mukherjee R, Hilliard E, Chakraborty P, Nasarre C, Yustein JT, Lang M, Jaffa AA, Mehrotra S, Klauber-DeMore N
Cancers 2021 May 30;13(11)
Cancers 2021 May 30;13(11)
The mRNA expression of Il6 and Pdcd1 are predictive and protective factors for doxorubicin‑induced cardiotoxicity.
Kanno SI, Hara A
Molecular medicine reports 2021 Feb;23(2)
Molecular medicine reports 2021 Feb;23(2)
Targeted elimination of myeloid-derived suppressor cells via regulation of the STAT pathway alleviates tumor immunosuppression in neuroblastoma.
Xu W, Li S, Li M, Yang X, Xie S, Lin L, Li G, Zhou H
Immunology letters 2021 Dec;240:31-40
Immunology letters 2021 Dec;240:31-40
Elevated lymphocyte specific protein 1 expression is involved in the regulation of leukocyte migration and immunosuppressive microenvironment in glioblastoma.
Cao JY, Guo Q, Guan GF, Zhu C, Zou CY, Zhang LY, Cheng W, Wang GL, Cheng P, Wu AH, Li GY
Aging 2020 Jan 29;12(2):1656-1684
Aging 2020 Jan 29;12(2):1656-1684
Berberine Maintains the Neutrophil N1 Phenotype to Reverse Cancer Cell Resistance to Doxorubicin.
Zhang S, Zhou L, Zhang M, Wang Y, Wang M, Du J, Gu W, Kui F, Li J, Geng S, Du G
Frontiers in pharmacology 2019;10:1658
Frontiers in pharmacology 2019;10:1658
Survival analysis with regard to PD-L1 and CD155 expression in human small cell lung cancer and a comparison with associated receptors.
Xu Y, Cui G, Jiang Z, Li N, Zhang X
Oncology letters 2019 Mar;17(3):2960-2968
Oncology letters 2019 Mar;17(3):2960-2968
m6A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade.
Yang S, Wei J, Cui YH, Park G, Shah P, Deng Y, Aplin AE, Lu Z, Hwang S, He C, He YY
Nature communications 2019 Jun 25;10(1):2782
Nature communications 2019 Jun 25;10(1):2782
Programmed cell death ligand 1 (PD-L1) expression is not a predominant feature in Ewing sarcomas.
Spurny C, Kailayangiri S, Jamitzky S, Altvater B, Wardelmann E, Dirksen U, Hardes J, Hartmann W, Rossig C
Pediatric blood & cancer 2018 Jan;65(1)
Pediatric blood & cancer 2018 Jan;65(1)
No comments: Submit comment
No validations: Submit validation data